Counseling for male BRCA mutation carriers - a review

Breast

Volumn 17, Issue 5, 2008, Pages 441-450

  Mohamad, Hussain B ^a   Apffelstaedt, Justus P ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

BRCA; Colon; Gastric cancer; Male; Pancreas; Prostate

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

AGE; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER RISK; COLORECTAL CANCER; GENE MUTATION; GENETIC COUNSELING; HEMATOLOGIC MALIGNANCY; HETEROZYGOSITY; HUMAN; LIVER METASTASIS; MALE; MEDICAL ASSESSMENT; MELANOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK MANAGEMENT; STOMACH CANCER;

EID: 53149125656     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2008.05.001     Document Type: Article

References (74)

1. Easton D., Steele L., Fields P., Ormiston W., Averill D., Daly P.A., et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. American Journal of Human Genetics 61 (1997) 120-128
2. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. Medscape General Medicine 7 2 (2005) 60
3. Scully R., and Livingston D.M. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408 6811 (2000 Nov 23) 429-432
4. Scully R., Puget N., and Vlasakova K. DNA polymerase stalling, sister chromatid recombination and the BRCA genes. Oncogene 19 53 (2000 Dec 11) 6176-6183
5. Wang Q., Zhang H., Fishel R., and Greene M.I. BRCA1 and cell signaling. Oncogene 19 53 (2000) 6152-6158
6. Zheng L., Li S., Boyer T.G., and Lee W.H. Lessons learned from BRCA1 and BRCA2. Oncogene 19 53 (2000 Dec 11) 6159-6175
7. Paull T.T., Rogakou E.P., Yamazaki V., Kirchgessner C.U., Gellert M., and Bonner W.M. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Current Biology 10 15 (2000 Jul 27) 886-895
8. Yamane K., Katayama E., and Tsuruo T. The BRCT regions of tumor suppressor BRCA1 and of XRCC1 show DNA end binding activity with a multimerizing feature. Biochemical and Biophysical Research Communications 279 2 (2000 Dec 20) 678-684
9. Tutt A., and Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends in Molecular Medicine 8 12 (2002 Dec) 571-576
10. Deng C.X., and Scott F. Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. Oncogene 19 8 (2000 Feb 21) 1059-1064
11. Welcsh P.L., and King M.C. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Human Molecular Genetics 10 7 (2001 Apr) 705-713
12. Ravandi-Kashani F., and Hayes T.G. Male breast cancer: a review of the literature. European Journal of Cancer 34 9 (1998 Aug) 1341-1347
13. Ford D., Easton D.F., Stratton M., Narod S., Goldgar D., Devilee P., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. American Journal of Human Genetics 62 3 (1998 Mar) 676-689
14. Friedman L.S., Gayther S.A., Kurosaki T., Gordon D., Noble B., Casey G., et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. American Journal of Human Genetics 60 2 (1997 Feb) 313-319
15. Thorlacius S., Sigurdsson S., Bjarnadottir H., Olafsdottir G., Jonasson J.G., Tryggvadottir L., et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. American Journal of Human Genetics 60 5 (1997 May) 1079-1084
16. Frank T.S., Deffenbaugh A.M., Reid J.E., Hulick M., Ward B.E., Lingenfelter B., et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. Journal of Clinical Oncology 20 6 (2002 Mar 15) 1480-1490
17. Rahman N., and Stratton M.R. The genetics of breast cancer susceptibility. Annual Review of Genetics 32 (1998) 95-121
18. Brose M.S., Rebbeck T.R., Calzone K.A., Stopfer J.E., Nathanson K.L., and Weber B.L. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. Journal of the National Cancer Institute 94 18 (2002 Sep 18) 1365-1372
19. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. Journal of the National Cancer Institute 91 15 (1999) 1310-1316
20. Ford D., Easton D.F., Bishop D.T., Narod S.A., Goldgar D.E., Haites N., et al. Risks of cancer in Brca1-mutation carriers. Lancet 343 8899 (1994 Mar 19) 692-695
21. Foulkes W.D., Brunet J.S., Warner E., Goodwin P.J., Meschino W., Narod S.A., et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. Journal of the National Cancer Institute 91 (1999) 1241-1247
22. Sigurdsson S., Thorlacius S., Tomasson J., Tryggvadottir L., Benediktsdottir K., Eyfjord J.E., et al. BRCA2 mutation in Icelandic prostate cancer patients. Journal of Molecular Medicine-JMM 75 10 (1997 Oct) 758-761
23. Struewing J.P., Hartge P., Wacholder S., Baker S.M., Berlin M., McAdams M., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New England Journal of Medicine 336 20 (1997 May 15) 1401-1408
24. Warner E., Foulkes W., Goodwin P., Meschino W., Blondal J., Paterson C., et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. Journal of the National Cancer Institute 91 14 (1999 July 21) 1241-1247
25. Nastiuk K.L., Mansukhani M., Terry M.B., Kularatne P., Rubin M.A., Melamed J., et al. Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate 40 3 (1999 Aug 1) 172-177
26. Hubert A., Peretz T., Manor O., Kaduri L., Wienberg N., Lerer I., et al. The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. American Journal of Human Genetics 65 3 (1999 Sep) 921-924
27. Vazina A., Baniel J., Yaacobi Y., Shtriker A., Engelstein D., Leibovitz I., et al. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. British Journal of Cancer 83 4 (2000 Aug) 463-466
28. Thompson D., and Easton D.F. Cancer incidence in BRCA1 mutation carriers. Journal of the National Cancer Institute 94 18 (2002 Sep 18) 1358-1365
29. Kirchhoff T., Kauff N., Kolachana P., Satagopan J., Mitra N., Huang H., et al. BRCA mutations and the risk of prostate and colorectal cancer in Ashkenazi Jews. American Journal of Human Genetics 73 5 (2003 Nov) 246
30. van Asperen C.J., Brohet R.M., Meijers-Heijboer E.J., Hoogerbrugge N., Verhoef S., Vasen H.F.A., et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. Journal of Medical Genetics 42 9 (2005 Sep) 711-719
31. Bermejo J.L., and Hemminki K. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing. Annals of Oncology 15 12 (2004 Dec) 1834-1841
32. Tryggvadottir L., Vidarsdottir L., Thorgeirsson T., Jonasson J.G., Olafsdottir E.J., Olafsdottir G.H., et al. Prostate cancer progression and survival in BRCA2 mutation carriers. Journal of the National Cancer Institute 99 12 (2007 June 20) 929-935
33. Johansson J.E., Andren O., Andersson S.O., Dickman P.W., Holmberg L., Magnuson A., et al. Natural history of early, localized prostate cancer. JAMA-Journal of the American Medical Association 291 22 (2004 June 9) 2713-2719
34. Shih H.A., Nathanson K.L., Seal S., Collins N., Stratton M.R., Rebbeck T.R., et al. BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. Clinical Cancer Research 6 11 (2000 Nov) 4259-4264
35. Goggins M., Schutte M., Lu J., Moskaluk C.A., Weinstein C.L., Petersen G.M., et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Research 56 23 (1996 Dec 1) 5360-5364
36. Hahn S.A., Greenhalf B., Ellis I., Sina-Frey M., Rieder H., Korte B., et al. BRCA2 germline mutations in familial pancreatic carcinoma. Journal of the National Cancer Institute 95 3 (2003 Feb 5) 214-221
37. Murphy K.M., Brune K.A., Griffin C., Sollenberger J.E., Petersen G.M., Bansal R., et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Research 62 13 (2002 July 1) 3789-3793
38. Risch H.A., McLaughlin J.R., Cole D.E.C., Rosen B., Bradley L., Kwan E., et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. American Journal of Human Genetics 68 3 (2001 Mar) 700-710
39. Niell B.L., Rennert G., Bonner J.D., Almog R., Tomsho L.P., and Gruber S.B. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. Journal of the National Cancer Institute 96 1 (2004 Jan 7) 15-21
40. Kirchhoff T., Satagopan J., Kauff N., Huang H., Kolachana P., Palmer C., et al. Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. Journal of the National Cancer Institute 96 (2004) 68-70
41. Evans H.S., Lewis C.M., Robinson D., Bell C.M.J., Moller H., and Hodgson S.V. Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England. British Journal of Cancer 84 3 (2001 Feb 2) 435-440
42. Friedenson B. The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BMC Cancer 7 (2007 Aug 6) 152
43. Hearle N., Damato B.E., Humphreys J., Wixey J., Green H., Stone J., et al. Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma. Investigative Ophthalmology & Visual Science 44 2 (2003 Feb) 458-462
44. Narod S.A., Brunet J.S., Ghadirian P., Robson M., Heimdal K., Neuhausen S.L., et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet 356 9245 (2000 Dec 2) 1876-1881
45. Tabar L., Vitak B., Chen H.H., Yen M.F., Duffy S.W., and Smith R.A. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer 91 9 (2001) 1724-1731
46. Daly M. NCCN practice guidelines: genetics/familial high-risk cancer screening. Oncology-New York 13 11A (1999 Nov) 161-182
47. Brenner R.J., Weitzel J.N., Hansen N., and Boasberg P. Screening-detected breast cancer in a man with BRCA2 mutation: case report. Radiology 230 2 (2004 Feb) 553-555
48. Munn S. Opinion. When should men undergo mammography?. American Journal of Roentgenology 178 6 (2002 June) 1419
49. Villers A., Rebillard X., Soulie M., Davin J.L., Coloby P., Moreau J.L., et al. Prostate cancer screening. Recommendations of the Association Francaise d'Urologie (AFU). Progres en Urologie 13 2 (2003 Apr) 209-214
50. Smith R.A., Cokkinides V., and Eyre H.J. American Cancer Society guidelines for the early detection of cancer. CA Cancer Journal for Clinicians 53 1 (2003 Jan) 27-43
51. Burke W., Daly M., Garber J., Botkin J., Kahn M.J.E., Lynch P., et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. 2. BRCA1 and BRCA2. JAMA-Journal of the American Medical Association 277 12 (1997 Mar 26) 997-1003
52. Brentnall T.A., Bronner M.P., Byrd D.R., Haggitt P.C., and Kimmey M.B. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Annals of Internal Medicine 131 4 (1999 Aug 17) 247-255
53. Brentnall T.A. Cancer surveillance of patients from familial pancreatic cancer kindreds. Medical Clinics of North America 84 3 (2000 May) 707-718
54. Canto M.I., Goggins M., Hruban R.H., Petersen G.M., Giardiello F.M., Yeo C., et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clinical Gastroenterology and Hepatology 4 6 (2006 June) 766-781
55. Hruban R.H., Canto M.I., and Yeo C.J. Prevention of pancreatic cancer and strategies for management of familial pancreatic cancer. Digestive Diseases 19 1 (2001) 76-84
56. Canto M.I., Goggins M., Yeo C.J., Griffin C., Axilbund J.E., Brune K., et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clinical Gastroenterology and Hepatology 2 7 (2004) 606-621
57. [Anon]. American Gastroenterological Association medical position statement: Epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 117 6 (1999 Dec) 1463-1464
58. Parker J.F., Florell S.R., Alexander A., DiSario J.A., Shami P.J., and Leachman S.A. Pancreatic carcinoma surveillance in patients with familial melanoma. Archives of Dermatology 139 8 (2003 Aug) 1019-1025
59. Ariga K., Honda T., Shintani S., Ito K., and Sato K. Gastric mass survey. Japanese Medical Journal 1754 (1957) 13-19
60. Matsumoto S., Yamasaki K., Tsuji K., and Shirahama S. Results of mass endoscopic examination for gastric cancer in Kamigotio Hospital, Nagasaki Prefecture. World Journal of Gastroenterology 13 32 (2007 Aug 28) 4316-4320
61. Layke J.C., and Lopez P.P. Gastric cancer: diagnosis and treatment options. American Family Physician 69 5 (2004 Mar 1) 1133-1140
62. Burke W., Petersen G., Lynch P., Botkin J., Daly M., Garber J., et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. 1. Hereditary nonpolyposis colon cancer. JAMA-Journal of the American Medical Association 277 11 (1997 Mar 19) 915-919
63. Walsh J.M.E., and Terdiman J.P. Colorectal cancer screening - scientific review. JAMA-Journal of the American Medical Association 289 10 (2003 Mar 12) 1288-1296
64. Couch F.J., Farid L.M., DeShano M.L., Tavtigian S.V., Calzone K., Campeau L., et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nature Genetics 13 1 (1996 May) 123-125
65. Haraldsson K., Loman N., Zhang Q.X., Johannsson O., Olsson H., and Borg A. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Research 58 7 (1998 Apr 1) 1367-1371
66. Csokay B., Udvarhelyi N., Sulyok Z., Besznyak I., Ramus S., Ponder B., et al. High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Research 59 5 (1999 Mar 1) 995-998
67. Sverdlov R.S., Barshack I., Bar Sade R.B., Baruch R.G., Hirsh-Yehezkel G., Dagan E., et al. Genetic analyses of male breast cancer in Israel. Genetic Testing 4 3 (2000) 313-317
68. Kwiatkowska E., Teresiak M., Lamperska K.M., Karczewska A., Breborowicz D., Stawicka M., et al. BRCA2 germline mutations in male breast cancer patients in the Polish population. Human Mutation 17 1 (2000) 73
69. Basham V.M., Lipscombe J.M., Ward J.M., Gayther S.A., Ponder B.A.J., Easton D.F., et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Research 4 1 (2002) R2
70. Ottini L., Masala G., D'Amico C., Mancini B., Saieva C., Aceto G., et al. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Research 63 2 (2003 Jan 15) 342-347
71. Giusti R.M., Rutter J.L., Duray P.H., Freedman L.S., Konichezky M., Fisher-Fischbein J., et al. A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. Journal of Medical Genetics 40 10 (2003 Oct 1) 787-792
72. Hamel N., Kotar K., and Foulkes W.D. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer. BMC Medical Genetics 4 (2003) 7
73. Drucker L., Stackievitz R., Shpitz B., and Yarkoni S. Incidence of BRCA1 and BRCA2 mutations in Ashkenazi colorectal cancer patients: preliminary study. Anticancer Research 20 1B (2000 Jan) 559-561
74. Chen-Shtoyerman R., Figer A., Fidder H.H., Rath P., Yeremin L., Bar Meir S., et al. The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients. British Journal of Cancer 84 4 (2001 Feb) 475-477